Cargando…

Axitinib Rechallenge Restores the Anticancer Effect after Nivolumab: A Case Report

The immune checkpoint inhibitor/tyrosine kinase inhibitor (ICI/TKI) combination treatment is currently the first-line treatment for metastatic renal cell carcinoma (mRCC). However, its efficacy beyond the third-line setting is expected to be relatively poor, and high-grade toxicities can develop by...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chang, Yueh-Shih, Chang, Pei-Hung, Wang, Deng-Huang, Chen, Chun-Bing, Huang, Chi-Ying F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10419223/ https://www.ncbi.nlm.nih.gov/pubmed/37569525 http://dx.doi.org/10.3390/ijms241512149

Ejemplares similares

Low-dose axitinib rechallenge with positive outcomes in a patient with metastatic renal cell carcinoma refractory to interferon α, sunitinib, axitinib, and nivolumab therapies: a case report
por: Murata, Masaki, et al.
Publicado: (2019)

REchallenge of NIVOlumab (RENIVO) or Nivolumab-Ipilimumab in Metastatic Renal Cell Carcinoma: An Ambispective Multicenter Study
por: Vauchier, Charles, et al.
Publicado: (2022)

Losartan Alleviates the Side Effects and Maintains the Anticancer Activity of Axitinib
por: Fu, Ying, et al.
Publicado: (2022)

Complete remission of brain metastases in renal cell carcinoma treated with axitinib after failure with nivolumab and ipilimumab treatment
por: Takayama, Koichiro, et al.
Publicado: (2022)

Successful rechallenge with cetuximab after progression with nivolumab for recurrent cervical lymph node metastasis from carcinoma of the tongue
por: Asada, Yasuyuki, et al.
Publicado: (2021)

Response to Ipilimumab/Nivolumab Rechallenge and BRAF Inhibitor/MEK Inhibitor Rechallenge in a Patient with Advanced Metastatic Melanoma Previously Treated with BRAF Targeted Therapy and Immunotherapy
por: Myrdal, Caitlyn N., et al.
Publicado: (2020)

Osimertinib‐related liver injury with successful osimertinib rechallenge: A case report
por: Cheng, Yuan‐Ling, et al.
Publicado: (2022)

Comparative Effectiveness of Front-Line Ipilimumab and Nivolumab or Axitinib and Pembrolizumab in Metastatic Clear Cell Renal Cell Carcinoma
por: Zarrabi, Kevin K, et al.
Publicado: (2022)

Dysphonia after Bevacizumab Rechallenge: A Case Report
por: Carter, Corey A., et al.
Publicado: (2015)

Rechallenge of lamotrigine after development of rash
por: Houser, Jennifer, et al.
Publicado: (2018)

Lithium rechallenge after renal transplant
por: Beasley, Anna K., et al.
Publicado: (2018)

5-Fluorouracil Rechallenge After Cardiotoxicity
por: Desai, Aakash, et al.
Publicado: (2020)

Current Status in Rechallenge of Immunotherapy
por: Hu, Han, et al.
Publicado: (2023)

Axitinib in combination with radiotherapy for advanced hepatocellular carcinoma: a phase I clinical trial
por: Yang, Kai-Lin, et al.
Publicado: (2021)

Selenium substituted axitinib reduces axitinib side effects and maintains its anti-renal tumor activity
por: Fu, Ying, et al.
Publicado: (2022)

RECOVERY AND RECHALLENGE AFTER THE NEUROLEPTIC MALIGNANT SYNOROME
por: Chopra, Mohit P., et al.
Publicado: (2001)

Melanoma: BRAFi Rechallenge
por: Kosmidis, Christoforos S., et al.
Publicado: (2023)

Cost-effectiveness comparison of cabozantinib with everolimus, axitinib, and nivolumab in the treatment of advanced renal cell carcinoma following the failure of prior therapy in England
por: Meng, Jie, et al.
Publicado: (2018)

Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US
por: Watson, Tina R., et al.
Publicado: (2020)

Axitinib/pembrolizumab: Tumour-lysis-syndrome: case report
Publicado: (2020)

A Case Report with Severe Thrombocytopenia Induced by Axitinib
por: Koksal, Ulkuhan I., et al.
Publicado: (2020)

Successful osimertinib rechallenge in a patient with advanced non-small cell lung cancer following osimertinib-induced interstitial lung disease after treatment with nivolumab
por: Mamesaya, Nobuaki, et al.
Publicado: (2017)

Rechallenge with Anti-PD-1 Inhibitors in Patients with Recurrent Gynecologic Malignancies
por: Kim, Migang, et al.
Publicado: (2023)

Rechallenge of voriconazole successfully tolerated after hepatic toxicity
por: Narumoto, O., et al.
Publicado: (2020)

Recurrence of Hypophysitis After Immune Checkpoint Inhibitor Rechallenge
por: Park, Benjamin C, et al.
Publicado: (2022)

The second docetaxel rechallenge for metastatic castration-resistant prostate cancer: a case report
por: Ning, Wei, et al.
Publicado: (2023)

Axitinib in Metastatic Renal Cell Carcinoma
por: Mittal, Kriti, et al.
Publicado: (2012)

Rechallenge capecitabine after fluoropyrimidine-induced cardiotoxicity in rectal cancer: A case report
por: Peng, Tao, et al.
Publicado: (2019)

Successful clozapine rechallenge after neutropenia using lithium carbonate : a case report
por: Khattech, D., et al.
Publicado: (2022)

Successful Trastuzumab-Deruxtecan Rechallenge After Interstitial Lung Disease: A Case Report
por: de Weger, Vincent A., et al.
Publicado: (2023)

Hyponatremia after initiation and rechallenge with trimethoprim–sulfamethoxazole in an older adult
por: Huntsberry, Ashley M, et al.
Publicado: (2015)

Non-Recurrence of Carbamazepine Induced Vitiligo after Rechallenge with Carbamazepine
por: Saeedloo, Masoomeh, et al.
Publicado: (2013)

Immune Checkpoint Inhibitor Rechallenge After Prior Immune Toxicity
por: Bylsma, Sophia, et al.
Publicado: (2022)

Zolpidem-induced sneezing: A case report of positive rechallenge
por: Amraei, Razie, et al.
Publicado: (2018)

ATLAS trial of adjuvant axitinib in patients with renal cell carcinoma: subgroup analyses with focus on axitinib dosing and racial groups
por: Quinn, D.I., et al.
Publicado: (2021)

Risperidone-Associated Neuroleptic Malignant Syndrome in an Inpatient With Schizophrenia, With Successful Rechallenge and 3 Year Follow-Up
por: Chen, Ting-Ren, et al.
Publicado: (2018)

KRAS-mutant colon cancer cells respond to combined treatment of ABT263 and axitinib
por: Wang, Guihua, et al.
Publicado: (2019)

Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers
por: Pithavala, Yazdi K., et al.
Publicado: (2010)

Axitinib for the Management of Metastatic Renal Cell Carcinoma
por: Escudier, Bernard, et al.
Publicado: (2012)

Axitinib: Newly Approved for Renal Cell Carcinoma
por: Tyler, Timothy
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_lr4npbbv5jvtc3a1v41uol2hnk